ACE2 and COVID-19: To elucidate whether the expression of DDC, ACE2, dACE2, or EPO are also altered in the nasopharyngeal tissue of COVID-19 patients with severe symptoms, we examined 21 samples obtained by SARS-CoV-2 infected patients admitted to the ICU and compared them to the Mild CoV-2 and Negative groups.